In favor of this idea, videomicroscopy analysis of the behavior of CML patient CD34+ cells in the presence or absence of imatinib showed no significant differences in motility (Supplementary Figure S1d). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.